| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 438 | 2021 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 328 | 2021 |
| Performance of VivaDiag COVID‐19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID‐19 in acute patients referring to emergency room department I Cassaniti, F Novazzi, F Giardina, F Salinaro, M Sachs, S Perlini, R Bruno, ... Journal of medical virology 92 (10), 1724, 2020 | 264 | 2020 |
| Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection N Sherina, A Piralla, L Du, H Wan, M Kumagai-Braesch, J Andréll, ... Med 2 (3), 281-295. e4, 2021 | 205 | 2021 |
| Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020 E Percivalle, G Cambiè, I Cassaniti, EV Nepita, R Maserati, A Ferrari, ... Eurosurveillance 25 (24), 2001031, 2020 | 196 | 2020 |
| Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit M Colaneri, E Seminari, S Novati, E Asperges, S Biscarini, A Piralla, ... Clinical Microbiology and Infection 26 (8), 1094. e1-1094. e5, 2020 | 159 | 2020 |
| Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant F Zuo, H Abolhassani, L Du, A Piralla, F Bertoglio, L de Campos-Mata, ... Nature communications 13 (1), 2670, 2022 | 132 | 2022 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 127 | 2022 |
| Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice R De Gasparo, M Pedotti, L Simonelli, P Nickl, F Muecksch, I Cassaniti, ... Nature 593 (7859), 424-428, 2021 | 111 | 2021 |
| EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count S Paolucci, I Cassaniti, F Novazzi, L Fiorina, A Piralla, G Comolli, R Bruno, ... International Journal of Infectious Diseases 104, 315-319, 2021 | 90 | 2021 |
| Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant M Schubert, F Bertoglio, S Steinke, PA Heine, MA Ynga-Durand, H Maass, ... BMC medicine 20 (1), 102, 2022 | 84 | 2022 |
| SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers F Rovida, I Cassaniti, S Paolucci, E Percivalle, A Sarasini, A Piralla, ... Nature communications 12 (1), 6032, 2021 | 62 | 2021 |
| SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay I Cassaniti, E Percivalle, F Bergami, A Piralla, G Comolli, R Bruno, ... Clinical Microbiology and Infection 27 (7), 1029-1034, 2021 | 60 | 2021 |
| Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic … S Bugatti, L De Stefano, S Balduzzi, MI Greco, T Luvaro, I Cassaniti, ... Annals of the Rheumatic Diseases 80 (12), 1635-1638, 2021 | 55 | 2021 |
| Immunity to SARS-CoV-2 up to 15 months after infection H Marcotte, A Piralla, F Zuo, L Du, I Cassaniti, H Wan, M Kumagai-Braesh, ... IScience 25 (2), 2022 | 54 | 2022 |
| Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 E Villa, R Critelli, S Lasagni, A Melegari, A Curatolo, C Celsa, ... Blood advances 5 (3), 662-673, 2021 | 54 | 2021 |
| Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection MA Avanzini, M Mura, E Percivalle, F Bastaroli, S Croce, C Valsecchi, ... Stem cells translational medicine 10 (4), 636-642, 2021 | 49 | 2021 |
| Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection I Cassaniti, AA Colombo, P Bernasconi, M Malagola, D Russo, AP Iori, ... American Journal of Transplantation 21 (4), 1622-1628, 2021 | 44 | 2021 |
| Members of the San Matteo Pavia COVID-19 Task Force. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to … I Cassaniti, F Novazzi, F Giardina, F Salinaro, M Sachs, S Perlini, R Bruno, ... J Med Virol 92 (10), 1724-7, 2020 | 44 | 2020 |
| West Nile or Usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors E Percivalle, I Cassaniti, A Sarasini, F Rovida, KMG Adzasehoun, ... Viruses 12 (2), 157, 2020 | 43 | 2020 |
